You are here
- Home
Total number of clinical trials
- collapse Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
- collapse A Phase I, 2-Part, Open-Label, Pharmacokinetic and Drug-Drug Interaction Study of CAZ104 (Avibactam and Ceftazidime in Healthy Subjects)
- collapse An Open-Label 52-week Study to Assess the Long-Term Safety of NKTR-118 in Opioid-Induced Constipation (OIC) in Patients With Non-Cancer-Related Pain
- collapse Open-Label Positron Emission Tomography Study with the Selective β Amyloid Radioligand [18F]AZD4694 to Assess the Effects of Varying Radioligand Mass on Binding Parameters in Healthy Volunteers and Patients with Alzheimer’s Disease
- collapse A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Metastatic, Gastric or Gastro-oesophageal Junction, Cancer Who Progress Following First Line Therapy and Are Ineligible for Treatment With Trastuzumab by HER2 Status (SAGE)
- collapse Prospective study to evaluate the impact of an educational programme about diabetes, comparing to normal clinical practice, on treatment compliance and disease control of people with type 2 diabetes followed in the primary care units in Portugal
- collapse A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study of AZD8931 In Combination with Anastrozole in Post menopausal Women With Hormone Receptor positive, Endocrine Therapy naive, Locally advanced or Metastatic Breast Cancer (MINT)
- collapse A Multicenter, observational, non-interventional registry designed to collect clinical data in Chinese patients who have received CUBICIN® treatment under condition of actual usage in clinical practice
- collapse A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, International Phase III Study With a 28-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10mg Once Daily in Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and Sulfonylurea
- collapse A 24-week National Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Trial in India to Evaluate the Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects with Type 2 Diabetes Who have Inadequate Glycaemic Control with Diet and Exercise alone.
